



Indiana
Department
of
Health

Long-term Care NEWSLETTER

LTC Newsletter 2023-22

Oct. 12, 2023

LTC Update:

- Adenosine Triphosphate (ATP) Luminometers Available for Facility Use
- Updated COVID-19 (2023-2024) Vaccines

Adenosine Triphosphate (ATP) Luminometers Available

Please complete a short survey if you would like to receive ATP equipment for use in your long-term care facility. The deadline has been extended from Oct. 15 to Oct. 20. If you have not already completed it, please fill out the [survey](#) by Oct. 20, to ensure you are on the distribution list.

Please gather the following information to answer the survey:

- Full name of the facility
- Exact shipping address
- Contact person's name, phone number, and email address
- Number of beds in the facility
- Number of ATP equipment requested
- It is recommended to request for one unit if the facility has fewer than 100 skilled nursing beds and two units if more 100 skilled nursing beds.
 - Facilities with high infection control needs such as MDRO unit/vent unit/high MDRO infections may request two units even if they have fewer than 100 beds.
 - Each facility must complete survey only once. If more than one survey is received, only the latest submission will be used in final planning.

Please see the [Long-term Care Newsletter Issue 2023-19](#), dated Sept. 14, for details.

Updated COVID-19 (2023-2024) Vaccines

COVID-19 updated (2023-2024) formula vaccines are now available and are recommended by Centers for Disease Control and Prevention (CDC). CDC recommends that people stay [up to date](#) with COVID-19 vaccination. The interim clinical considerations can be accessed [here](#).

The 2023–24 formulation for all COVID-19 vaccines licensed or authorized in the United States (Moderna, Novavax, and Pfizer-BioNTech) has been updated to a monovalent vaccine based on the Omicron XBB.1.5 sublineage of SARS-CoV-2. The original monovalent and bivalent (Original and Omicron BA.4/BA.5) formulations should no longer be used. There is no preferential recommendation for the use of any one COVID-19 vaccine over another when more than one recommended and age-appropriate vaccine is available.

Vaccination schedules can be found in [Table 1](#) for people who are not moderately or severely immunocompromised and in [Table 2](#) for people who are moderately or severely immunocompromised. See [Appendix A](#) for recommendations for people who received COVID-19 vaccine outside the United States.